Search

everythinglearnresearchcommunity

for

Search:↓

Compounds 15, 20, and 25 are strong inhibitors of human steroid 5α-reductase type 2.

Different halogens on progesterone derivatives can either block or mimic male hormone effects, depending on their type and amount.

Minoxidil analogs can be improved for hair growth inhibition by modifying specific parts of their structure.

Some new progesterone derivatives are better at blocking testosterone conversion than a common drug.

Synthetic curcumin derivatives improve treatment for diabetes and cancer.

Compounds 4, 4b, and 4c effectively inhibit an enzyme linked to testosterone conversion without significant toxicity.

A new method creates valuable compounds for drug discovery by breaking traditional chemical rules.

New steroids were patented as effective for treating acne, hair loss, and other conditions related to hormones.

New chemicals were made that can block an enzyme linked to hair loss, prostate growth, and acne.

A brominated phenoxy compound effectively inhibits a human enzyme and shows potential for clinical use.

New minoxidil compounds with better water solubility were made, but their full effects and safety need more research.

New substances were created that improve health and may treat dementia, osteoporosis, and cancer.

New steroid compounds may help with hormonal therapy and have potential benefits for glucose disorders, but more research is needed.

Metabolite 7 is a strong inhibitor for Alzheimer's disease management.

Certain progesterone derivatives can inhibit enzymes and reduce androgenic activity, potentially affecting prostate growth.

Certain compounds reduced hamster flank organ size by inhibiting 5α-reductase, like finasteride, without affecting androgen receptors.

A new antiandrogen compound was made and its detailed three-dimensional shape was described.

The document concludes that scientists created various steroids with different properties, including a more effective semi-synthetic vitamin D.

New compounds were made and tested, with compound 6 showing potential for treating prostate-related diseases.

CMC2.24 and CMC2.23 reduce melanin safely and effectively.

MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.

Compound 7b is a promising candidate for treating benign prostatic hyperplasia and prostate cancer.

Some minoxidil combinations can help differentiate leukemia cells without harming other cells.

2,5-DBH shows promise for improving drugs in cancer, brain disorders, and infections.

New nonsteroidal molecules can potentially increase dihydrotestosterone in neurons by blocking certain enzymes, without affecting prostate and seminal vesicle weight.

The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.

New method makes important drug ingredients more easily without needing extra purification steps.

A new compound, 3a, effectively fights prostate cancer better than finasteride.